达格列净对2型糖尿病合并高血压病患者血压变异性和左心室质量指数作用的研究

Influences of dapagliflozin on blood pressure variability and left ventricular mass index in patients with type 2 diabetes mellitus and hypertensi

目的探究达格列净对2型糖尿病(T2DM)合并高血压病患者血压变异性(BPV)和左心室质量指数(LVMI)的作用。方法选择2021年8月至2022年8月丽水市中心医院收治的T2DM合并高血压病患者为研究对象,分别给予常规治疗(对照组)和达格列净治疗(试验组)。比较两组患者的BPV指标、LVMI、血糖水平的变化及不良反应发生率。结果研究共纳入94例T2DM合并高血压病患者,试验组和对照组各47例。两组T2DM合并高血压病患者的24 h舒张压均数(DBP)、24 h收缩压均数(SBP)、24 h收缩压标准差(SSD)、24 h舒张压标准差(DSD)、空腹血糖(FBG)、2 h血糖(PG)、糖化血红蛋白(HbA1c)、体重指数(BMI)及LVMI显著降低(P<0.05),且试验组的24 h SBP、24 h DBP、24 h SSD、24 h DSD、FPG、2 h PG、HbA1c、BMI及LVMI均低于对照组(P<0.05)。试验组与对照组的不良反应总发生率分别为10.64%和4.26%,差异无统计学意义(P>0.05)。结论达格列净可降低T2DM合并高血压病患者LVMI,改善患者BPV及血糖水平,且安全性较好。

Objective To investigate the effect of dapagliflozin on blood pressure variability(BPV)and left ventricular mass index(LVMI)in patients with type 2 diabetes mellitus(T2DM)and hypertension.Methods Patients with T2DM complicated with hypertension admitted to Lishui Central Hospital from August 2021 to August 2022 were selected as the study subjects,and were treated with conventional treatment(control group)and dapagliflozin treatment(test group),respectively.The changes of BPV index,LVMI,blood glucose level and the incidence of adverse reactions were compared between the two groups.Results A total of 94 patients with T2DM and hypertension were included in the study,including 47 patients in the test group and 47 in the control group.The 24-hour diastolic blood pressure(DBP),24-hour systolic blood pressure(SBP),24-hour systolic standard deviation(SSD),24-hour diastolic standard deviation(DSD),fasting blood glucose(FBG),2-hour blood glucose(PG),glycated hemoglobin glycosylated hemoglobin(HbA1c),body mass index(BMI)and LVMI of the patients with T2DM and hypertension were significantly decreased in the two groups(P<0.05),and the 24-hour SBP,24-hour DBP,24-hour SSD,24-hour DSD,FPG,2-hour PG,HbA1c,BMI and LVMI in the test group were lower than those in the control group(P<0.05).The total incidence of adverse reactions between the test group and the control group was 10.64%and 4.26%,respectively,and the difference was not statistically significant(P>0.05).Conclusion Dapagliflozin can reduce LVMI and improve BPV and blood glucose levels in patients with T2DM and hypertension,and has a good safety profile.